Skip to main content
. 2021 Jun 4;279(3):1371–1381. doi: 10.1007/s00405-021-06916-0

Fig. 3.

Fig. 3

Distribution (% of patients) of endonasal oedema severity scores (0 = no symptoms, 4 = very strong symptoms) at V1 and V2: patients were either treated with Ectoin® Rhinitis Nasal Spray (SNS01), Ectoin® Rhinitis Nasal Spray + Xylometazoline nasal spray (Xylo/SNS01) or Xylometazoline nasal spray (Xylomet)